scispace - formally typeset
M

Miguel Ángel Descalzo

Researcher at Carlos III Health Institute

Publications -  109
Citations -  3352

Miguel Ángel Descalzo is an academic researcher from Carlos III Health Institute. The author has contributed to research in topics: Population & Adverse effect. The author has an hindex of 27, co-authored 105 publications receiving 2999 citations. Previous affiliations of Miguel Ángel Descalzo include Universidad Camilo José Cela & University of Santiago de Compostela.

Papers
More filters
Journal ArticleDOI

Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.

TL;DR: New cases of ATB still occur in patients treated with all available TNF antagonists due to lack of compliance with recommendations to prevent reactivation of LTBI, and continuous evaluation of recommendations is required to improve clinical practice.
Journal ArticleDOI

All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists

TL;DR: Morbidity, other than infection, and mortality are not higher than expected in patients with RA treated with TNF antagonists, according to a comparison with BIOBADASER.
Journal ArticleDOI

The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry

TL;DR: The incidence of early arthritis (EA) and of RA in adults (>16 yrs) in adults in Spain is estimated to be about three times that of RA.
Journal ArticleDOI

Seasonal trends and spatial relations between environmental/meteorological factors and leishmaniosis sand fly vector abundances in Central Spain

TL;DR: An entomological survey performed over the period 2006-2008 in Central Spain where canine leishmaniosis (CanL) is endemic found that the vectors are moving towards higher altitudes perhaps because of global change, which could have an impact on CanL and its geographical distribution.